Myopia Control and Prevention Strategies

Myopia now affects roughly 30% of the global population — a figure the Brien Holden Vision Institute projects will climb to 50% by 2050, with approximately 938 million people reaching high myopia (−6.00 diopters or worse) (BHVI, 2016). That trajectory isn't just an inconvenience measured in thicker lenses. High myopia carries a substantially elevated risk of retinal detachment, glaucoma, macular degeneration, and cataract — conditions that can permanently impair vision. The public health math here is significant, and the clinical response has matured considerably over the past two decades.

What Drives Myopia Progression?

Myopia develops when the axial length of the eye grows longer than its optical power requires, causing light to focus in front of the retina rather than on it. The two most studied drivers are genetic predisposition and environmental exposure — particularly time spent on near-work tasks and time not spent outdoors.

The outdoor effect has been replicated in landmark work from the Sydney Myopia Study and the COMET (Correction of Myopia Evaluation Trial), among others. A meta-analysis published in Ophthalmology (2015) found that each additional hour of outdoor time per week was associated with a 2% reduced odds of myopia (PMC4270813). Bright natural light appears to stimulate retinal dopamine release, which signals the eye to slow axial elongation — a mechanism confirmed in animal models at institutions including the New England College of Optometry.

Children in East Asian countries — particularly Singapore, China, South Korea, and Taiwan — show myopia prevalence rates exceeding 80% in urban adolescent populations (WHO, 2019). The convergence of intensive near-work demands and reduced outdoor time in these educational environments offers a fairly clean natural experiment.

Evidence-Based Control Strategies

Atropine Eye Drops

Low-dose atropine (0.01% to 0.05%) is one of the most studied pharmaceutical interventions for myopia control. The ATOM2 trial, conducted at the Singapore National Eye Centre, demonstrated that 0.01% atropine slowed axial elongation significantly over two years while producing minimal side effects compared to higher concentrations. The 0.01% concentration showed the best balance of efficacy and rebound effect management (Chia et al., Ophthalmology, 2012). As of the LAMP study (Low-Concentration Atropine for Myopia Progression, Hong Kong), 0.05% atropine demonstrated a 67% reduction in myopia progression over 12 months compared to placebo.

Orthokeratology

Orthokeratology (ortho-k) uses specially designed rigid gas-permeable contact lenses worn overnight. They temporarily reshape the corneal surface, correcting daytime vision without spectacles — but their myopia-control value is in what they do to peripheral retinal defocus. Multiple prospective studies, including the LORIC (Longitudinal Orthokeratology Research in Children) study from Hong Kong Polytechnic University, found a roughly 46% reduction in axial elongation compared to single-vision spectacle controls over 24 months (Cho et al., Optometry & Vision Science, 2005).

Multifocal and Peripheral Defocus Spectacle Lenses

Defocus Incorporated Multiple Segments (DIMS) lenses, developed by Hong Kong Polytechnic University, generated peer-reviewed data showing a 52% reduction in myopia progression and 62% reduction in axial elongation over two years in children aged 8–13 (Lam et al., Ophthalmology, 2020). The mechanism targets the peripheral retinal signal hypothesis — a slightly myopic peripheral defocus is introduced across the lens while maintaining clear central vision. DIMS lenses reached commercial distribution under the brand name MiyoSmart (Hoya Vision Care).

Separate designs under the MiSight 1 day brand (CooperVision) use a concentric ring approach and received U.S. FDA clearance in 2019, supported by a 3-year clinical trial showing a 59% reduction in myopia progression versus single-vision controls (CooperVision/FDA 510(k) data, 2019).

Soft Multifocal Contact Lenses

Standard multifocal soft lenses, originally designed for presbyopia, have shown modest myopia-control effects. The BLINK (Bifocal Lenses In Nearsighted Kids) study, a randomized clinical trial funded by the National Eye Institute, found that high-add power (+2.50 D) multifocal contact lenses reduced myopia progression by approximately 0.40 D over 3 years compared to single-vision lenses (Walline et al., JAMA, 2020).

Behavioral and Environmental Interventions

The "20-20-20 rule" — a 20-second break looking at a distance of 20 feet every 20 minutes — lacks high-quality randomized trial support as a standalone myopia control measure, but it reflects the broader principle of reducing sustained near work. What has stronger evidence is structured outdoor time. Taiwan's government launched a national outdoor recess program requiring 120 minutes of outdoor exposure per school day; an evaluation at 571 elementary schools showed a significant reduction in new myopia onset compared to historical rates (Wu et al., Ophthalmology, 2013).

Who Benefits from Intervention and When?

Myopia control is most effective when initiated early, before axial elongation accelerates. Children who develop myopia before age 10 carry the highest lifetime risk of high myopia. The International Myopia Institute's 2019 white papers — produced by a working group that included researchers from Cardiff University, the University of Houston, and the University of Auckland — recommend discussing intervention at the first confirmed myopic refraction in children, rather than waiting for progression (IMI, 2019).

No intervention reverses existing myopia. The goal is slowing axial elongation to reduce the lifetime endpoint refraction and, by extension, reduce the probability of serious sight-threatening complications later in life. A child who ends up at −3.00 D instead of −6.00 D faces dramatically different risk odds for retinal pathology.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)